NextCure (2US0) Stock Forecast & Price Target
0 Followers
2US0 Analyst Ratings
Moderate Buy
1Buy0Hold0Sell
Based on 1 analysts giving stock ratings to NextCure in the past 3 months
2US0 Stock 12 Month Forecast
Average Price Target
EUR 17.85▲(277.58% Upside)Based on 1 Wall Street analysts offering 12 month price targets for NextCure in the last 3 months. The average price target is EUR 17.85 with a high forecast of EUR 17.85 and a low forecast of EUR 17.85. The average price target represents a 277.58% change from the last price of EUR 4.73.
Past 12 Months12 Month ForecastDec2025Sep2026
HighEUR 17.85
AverageEUR 17.85
LowEUR 17.85
Highest Price TargetHighestEUR 17.85Average Price TargetEUR 17.85Lowest Price TargetLowestEUR 17.85
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Emily Bodnar | H.C. Wainwright | EUR 17.85 | buy | 277.58%Upside | Reiterated | 08/13/26 | ||
| Edward Tenthoff | Piper Sandler | EUR 13.39 | buy | 183.18%Upside | Reiterated | 06/10/26 | ||
| Christopher Liu | Lucid Capital | EUR 22.31 | buy | 371.97%Upside | Reiterated | 06/02/26 | ||
| Kevin DeGeeter | Ladenburg Thalmann & Co. | EUR 16.06 | buy | 239.82%Upside | Upgraded | 11/07/25 |
| Rating | Follow | Article | |||
|---|---|---|---|---|---|
| Emily BodnarH.C. Wainwright | BuyReiteratedEUR 17.85 | 08/13/26 | 277.58%Upside | ||
| Edward TenthoffPiper Sandler | BuyReiteratedEUR 13.39 | 06/10/26 | 183.18%Upside | ||
| Christopher LiuLucid Capital | BuyReiteratedEUR 22.31 | 06/02/26 | 371.97%Upside | ||
| Kevin DeGeeterLadenburg Thalmann & Co. | BuyUpgradedEUR 16.06 | 11/07/25 | 239.82%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering NextCure
3 Months
Success Rate8/15 ratings generated profit
53%
Average Return
-0.71%
Copying Emily Bodnar's trades and holding each position for 3 Months would result in 53.33% of your transactions generating a profit, with an average return of -0.71% per trade.
1 Year
Success Rate5/11 ratings generated profit
45%
Average Return
+2.96%
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of +2.96% per trade.
2 Years
Success Rate3/15 ratings generated profit
20%
Average Return
-29.29%
Copying Emily Bodnar's trades and holding each position for 2 Years would result in 20.00% of your transactions generating a profit, with an average return of -29.29% per trade.
2US0 Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 2 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 3 | 4 | 4 | 2 | 1 |
In the current month, 2US0 has received 1 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 2US0 average Analyst price target in the past 3 months is 17.85.
2US0 Financial Forecast
ConsensusEUR 0.00
2US0 Sales Forecast
Next quarter’s sales forecast for 2US0 is EUR 0 with a range of ― to ―. The previous quarter’s sales results were EUR 0. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
2US0 Stock Forecast FAQ
What is DE:2US0’s average 12-month price target, according to analysts?
Based on analyst ratings, NextCure’s 12-month average price target is €17.85.
What is DE:2US0’s upside potential, based on the analysts’ average price target?
NextCure has 277.58% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is NextCure a Buy, Sell or Hold?
NextCure has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
What is NextCure’s share price target?
The average share price target for NextCure is €17.85. This is based on 1 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €17.85, and the lowest forecast is €17.85. The average share price target represents a 277.58% increase from the current price of €4.727.
What do analysts say about NextCure?
NextCure’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Street analysts.
How can I buy shares of NextCure?
To buy shares of DE:2US0, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
